
    
      A Phase 3 Study comparing 80 mg, 120 mg or 240 mg of febuxostat, allopurinol (300 mg for
      those with normal renal function and 100 mg for those with impaired renal function) and
      placebo administered once daily in subjects with gout.

      Subjects will receive treatment for 28 weeks.
    
  